The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.
about
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Diffuse large B-cell lymphoma in elderly: Experience from a tertiary care oncology center in South India.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentEBV-positive diffuse large B-cell lymphoma of the elderlyAggressive B-cell lymphomas: how many categories do we need?Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab eraImmunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.Management Strategies for Elderly Patients with Diffuse Large B-Cell LymphomaComparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.Treatment of the elderly patient with diffuse large B cell lymphoma.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study.Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment.Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup.Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup (Reply).Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study.Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.The impact of age on survival of diffuse large B-cell lymphoma - a population-based study.Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.Incidence and survival of hematological cancers among adults ages ≥75 years.Management of aggressive lymphoma in very elderly patients.Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspectiveImmunosenescence and lymphomagenesis
P2860
Q28088365-970EC9EC-3493-44FE-A06A-1C6430FD12E3Q30235296-66CDD648-901C-453C-9447-1251412EFCCCQ33896966-E4AB1A42-22C6-4BE1-BC67-86E7F9007E95Q33945770-CFDE705D-FCF9-4814-8E0F-C0FA118869C1Q34343242-EE3045ED-8E4C-43CE-A201-B158275A69B8Q35527893-79AAC90F-4ACD-4452-BF56-D1BE832517BFQ35713686-1B915EB7-3892-4C41-A91E-99411F58F0EAQ36140942-5B7DBA4D-B86F-47B9-B777-AAF87685B9FCQ36274840-4D3CFCC3-6943-4720-AAC1-7ED6A0BE842DQ36302961-4B3D5E47-0D0E-4DDF-9D3C-BACDED067912Q36949798-D3C2993B-32EB-4883-B11F-D6B483A35F78Q37120684-678636AC-E286-44E6-A47D-521948E16CC8Q37998553-1685E241-3120-4FDF-96CC-0915F44DF29EQ38240579-D73BE4A9-0403-43FA-94EA-DDACE5B8A695Q38609747-DE6FAE4D-4501-4D5E-82E3-E5A0B453B6A5Q38664822-EEF40780-64C7-422C-B9B1-F6940AFF137AQ38982196-E15262F8-15A2-4C51-A0E1-CC7EFB5C493EQ40576636-9B637B10-EF8F-4142-AF2D-E0C5EF4CAA94Q41661509-F1D5B8C5-E0AC-43F4-B4D6-E4B2A86A201CQ43067064-A2C712F8-7A30-48C1-8A60-6D5823D29CE9Q43485442-322D81F1-B516-4955-9A50-97EE53C5186DQ46455259-23D03DB4-9472-4FBA-B403-2D9342266550Q48229580-F76B4196-CE22-4C0C-85F1-7B8CBC445B03Q48234935-BD2D1D99-BA55-4A77-8616-D341E1CF9C46Q48933203-6F5F8390-9201-4D14-8E0D-EF1FF5130DB9Q51767473-4C763873-0D31-4186-94E6-B0900CC510F9Q53079506-588E01CC-8800-4408-B2E3-78FA45556A0FQ53079564-066710F1-AFDC-4BAB-9B53-C58518F997ABQ53117498-7E733B91-636C-4713-9973-38428D59C30FQ53649129-61993F29-B03F-44EA-B7BC-3D91F3B1AC43Q54342150-F83D3F4F-16D4-4A66-92B0-3299194C2C27Q55299219-53236318-9983-477B-8C1C-A1BF9F7EC513Q57174502-03459EBE-36B9-492E-B59B-679AA3537DBEQ58706440-B3449A66-0257-4834-AC41-B47EB5A36653
P2860
The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The proportion of activated B- ...... l lymphoma increases with age.
@en
The proportion of activated B- ...... l lymphoma increases with age.
@nl
type
label
The proportion of activated B- ...... l lymphoma increases with age.
@en
The proportion of activated B- ...... l lymphoma increases with age.
@nl
prefLabel
The proportion of activated B- ...... l lymphoma increases with age.
@en
The proportion of activated B- ...... l lymphoma increases with age.
@nl
P2093
P2860
P1433
P1476
The proportion of activated B- ...... ll lymphoma increases with age
@en
P2093
Christian Bastard
Fabrice Jardin
Hervé Tilly
Hélène Lanic
Philippe Ruminy
P2860
P304
P356
10.3324/HAEMATOL.2011.050617
P577
2011-08-22T00:00:00Z